Phase IIA
A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy
- Study HIC#:2000030395
- Last Updated:04/21/2023
The purpose of this study is to determine whether CVL-871 is safe and tolerable in patients with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.
- Age50 years - 85 years
- GenderBoth
Contact Us
For more information about this study, including how to volunteer, contact:
Carol Gunnoud
- Phone Number: 1-203-764-8100
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Trial Purpose and Description
The purpose of this study is to determine whether CVL-871 is safe and tolerable in patients with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.
Eligibility Criteria
Inclusion Criteria:
- Meets diagnostic criteria for apathy in neurocognitive disorders clinically significant apathy
- Mild to Moderate Dementia (AD, FTD, VAD, or DLB)
Exclusion Criteria:
- Other significant psychiatric disorder(s)
- Other neurological disorders (other than AD, FTD, VAD, or DLB)
